ReviewProtein & cell2015
New discovery rarely runs smooth: an update on progranulin/TNFR interactions.
Review in Protein & cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 45 citations in OpenAlex.
- Preclinical and clinical investigation of VES001, an oral small molecule sortilin receptor inhibitor for the treatment of frontotemporal dementia: a first-in-human randomized placebo-controlled phase 1 trial.Nature communications · 2026Trial
- Progranulin serum levels in human kidney transplant recipients: A longitudinal study.PloS one · 2018Trial
- Progranulin: A promising biomarker and therapeutic target for fibrotic diseases.Acta pharmaceutica Sinica. B · 2024Review
- Review
- Regulation of extracellular progranulin in medial prefrontal cortex.Neurobiology of disease · 2023Article
- Injectable hydrogel for sustained delivery of progranulin derivative Atsttrin in treating diabetic fracture healing.Biomaterials · 2023Article
- The Role of Progranulin (PGRN) in the Pathogenesis of Ischemic Stroke.Cellular and molecular neurobiology · 2023Review
- Progranulin Oncogenic Network in Solid Tumors.Cancers · 2023Review
- Adipokines, adiposity, and atherosclerosis.Cellular and molecular life sciences : CMLS · 2022Review
- Progranulin promotes bone fracture healing via TNFR pathways in mice with type 2 diabetes mellitus.Annals of the New York Academy of Sciences · 2021Article
- Tweaking Progranulin Expression: Therapeutic Avenues and Opportunities.Frontiers in molecular neuroscience · 2021Review
- In Vitro Physical and Functional Interaction Assays to Examine the Binding of Progranulin Derivative Atsttrin to TNFR2 and Its Anti-TNFα Activity.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Progranulin Regulates Inflammation and Tumor.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2020Review
- Progranulin promotes diabetic fracture healing in mice with type 1 diabetes.Annals of the New York Academy of Sciences · 2020Article
- Progranulin Improves Acute Lung Injury through Regulating the Differentiation of Regulatory T Cells and Interleukin-10 Immunomodulation to Promote Macrophage Polarization.Mediators of inflammation · 2020Article
- Progranulin autoantibodies in systemic sclerosis and autoimmune connective tissue disorders: A preliminary study.Immunity, inflammation and disease · 2019Article
- Atsttrin reduces lipopolysaccharide-induced neuroinflammation by inhibiting the nuclear factor kappa B signaling pathway.Neural regeneration research · 2019Article
- Progranulin attenuates liver fibrosis by downregulating the inflammatory response.Cell death & disease · 2019Article
- Microglial Progranulin: Involvement in Alzheimer's Disease and Neurodegenerative Diseases.Cells · 2019Review
- Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease.Journal of molecular medicine (Berlin, Germany) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progranulin (PGRN) is a growth factor implicated in various pathophysiological processes, including wound healing, inflammation, tumorigenesis, and neurodegeneration. It was previously reported that PGRN binds to tumor necrosis factor receptors (TNFR) and has therapeutic effects in inflammatory arthritis (Tang et. al, in Science 332:478-484, 2011); however, Chen et al. reported their inability to demonstrate the PGRN-TNFR interactions under their own conditions (Chen et. al, in J Neurosci 33:9202-9213, 2013). A letter-to-editor was then published by the original group in response to the Chen et al. paper that discussed the reasons for the latter's inability to recapitulate the interactions. In addition, the group published follow-up studies that further reinforced and dissected the interactions of PGRN-TNFR. Recently, the dispute about the legitimacy of PGRN-TNFR interactions appears to be finally settled with independent confirmations of these interactions in various conditions by numerous laboratories. This review presents a chronological update on the story of PGRN-TNFR interactions, highlighting the independent confirmations of these interactions in various diseases and conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.